Breast Cancer CDK4/6
Hormone Receptor-Positive Advanced/Metastatic Breast Cancer: A Deeper Look into CDK4/6 Inhibitors
Speakers: Richard S. Finn, MD, Associate Professor of Medicine, Division of Hematology/Oncology
Duration: 60 minutes
Presented on: June 28, 2017
Richard S. Finn, MD
Richard S. Finn, MD
Associate Professor of Medicine, Division of Hematology/OncologyRichard S. Finn, MD, is an assistant professor of medicine in the Department of Medicine, Division of Hematology/ Oncology, at the Geffen School of Medicine at the University of California, Los Angeles (UCLA). He currently splits his time between patient care and directing the Translational Research Laboratory in the Division of Hematology/ Oncology. Dr Finn’s research interests are focused in the development of targeted therapeutics for solid tumors across histologies, while his personal interests lie in the development of these targeted agents in hepatobiliary and breast cancers. He earned his medical degree at the Keck School of Medicine of the University of Southern California, and completed his clinical training in internal medical and hematology/oncology at UCLA.
HORMONE RECEPTOR-POSITIVE ADVANCED/METASTATIC BREAST CANCER: A DEEPER LOOK INTO CDK4/6 INHIBITORS
Presented by the Albert Einstein College of Medicine and Montefiore Medical Center in Joint Providership with PlatformQ Health Education, LLC
ACKNOWLEDGEMENT This activity is supported by an independent educational grant from Novartis.
ACCREDITATION STATEMENT The activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine and PlatformQ Health Education, LLC. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENTS Live Activity Albert Einstein College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Enduring Material Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
OTHER CREDITS The American Academy of Nurse Practitioners (AANP) and American Nurses Credentialing Center (ANCC) accept AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
DATE OF RELEASE/EXPIRATION Live Activity Wednesday, June 28, 2017 from 1:00 PM EST – 2:00 PM EST Enduring Material The enduring material will be available from June 28, 2017 to December 28, 2017.
LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to:
• Address the current advances and challenges of treating HR+, HER2- advanced and metastatic breast cancer • Evaluate new safety and efficacy data of CDK4/6 inhibitors for HR+, HER2- advanced and metastatic breast cancer • Anticipate and plan effective strategies to manage CDK4/6 inhibitor treatment-related side effects
TARGET AUDIENCE Medical, radiation and surgery oncologists, breast surgeons, oncology nurse practitioners, pharmacists, and other health care professionals who treat patients with breast cancer
ESTIMATED TIME TO COMPLETE This activity consists of one session, which should take approximately 1 hour to complete.
METHOD OF PARTICIPATION There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. It is estimated that this module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the posttest.
HARDWARE/SOFTWARE REQUIREMENTS Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
FACULTY DISCLOSURE The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.
TThe Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.
Presenters Disclosures Richard S. Finn, MD
Consultant: Pfizer, Novartis Contracted Research/Principal Investigator: Pfizer Contracted to the University of California at Los Angeles
Hamsa Jaganathan, PhD
Has nothing to disclose relevant to this activity.
Peer Reviewer Disclosures Jesus Anampa Mesias, MD Has nothing to disclose relevant to this activity. Providers Disclosures Einstein-Montefiore Center for Continuing Medical Education The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine has no disclosures to report relevant to this activity. PlatformQ Health Education, LLC Disclosures Hamsa Jaganathan, Medical Director Has nothing to disclose relevant to this activity. Elizabeth del Nido, Program Manager Has nothing to disclose relevant to this activity.
CONTACT INFORMATION Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to email@example.com. For issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.
DISCLAIMERS (if applicable): The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material. The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by Albert Einstein College of Medicine, OMedLive, PlatformQ Health Education, LLC or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.